周四盘中，CRO（合同研究组织）龙头企业Medpace Holdings Inc.（MEDP）股价大涨5.21%，延续了此前的强劲涨势。这一涨幅主要受到公司发布的2025年第二季度业绩报告及全年业绩指引上调的推动。
据报道，Medpace公布的2025年第二季度业绩表现亮眼。公司收入达6.033亿美元，同比增长14.2%；税息折旧及摊销前利润（EBITDA）为1.305亿美元，同比增长16.2%。更引人注目的是，公司新增业务合同达6.205亿美元，较去年同期增长12.6%，显示出业务需求的强劲复苏。
Medpace管理层还大幅上调了2025年全年业绩预期，预计全年收入将达到24.20亿-25.20亿美元，较2024年增长14.7%-19.5%。这一预测远超此前市场预期，暗示公司可能已经走出2024年的业务低迷期。分析人士指出，Medpace的业绩反弹可能预示着生物科技行业整体投资热情的回升，尤其是在中小型生物制药公司领域。投资者对这一积极信号反应强烈，推动Medpace股价持续上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.